Your session is about to expire
← Back to Search
Carbohydrate Binding Protein Inhibitor
Intervention for Osteoarthritis
Phase 3
Waitlist Available
Led By Mark Fisher
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
Study Summary
The proposed study is a pilot, double-blind, randomized clinical trial comparing galectin-3 inhibition with MCP to placebo for the treatment of knee osteoarthritis.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
WOMAC-Knee
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: InterventionActive Control1 Intervention
Patients will be given Modified Citrus Pectin twice daily for 12 weeks, and have their change in knee pain as measured by survey instruments assessed
Group II: ControlPlacebo Group1 Intervention
Patients will be given placebo twice daily for 12 weeks, and have their change in knee pain as measured by survey instruments assessed
Find a Location
Who is running the clinical trial?
Massachusetts General HospitalLead Sponsor
2,932 Previous Clinical Trials
13,198,445 Total Patients Enrolled
20 Trials studying Osteoarthritis
4,580 Patients Enrolled for Osteoarthritis
Mark FisherPrincipal InvestigatorMGH
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger